Aktien Sensor

SOBI is set to release its Q1 2025 earnings on April 29, with Berenberg reaffirming its buy recommendation and lowering its price target to 360 kronor.

SOBI’s Annual Report highlights the company’s efforts to develop rare disease therapies, but raises questions about its commitment to sustainability and innovation, leaving shareholders and stakeholders uncertain about its future direction.